Enzyme-activated peptide prodrug targets Pseudomonas in laboratory biofilms

What happened

A laboratory study posted by ACS Infectious Diseases on August 21 describes an antimicrobial peptide prodrug designed to exploit an enzyme produced by *Pseudomonas aeruginosa*. The engineered molecule killed the bacterium in free-living cultures and laboratory biofilms while showing less activity against several other bacterial pathogens.

The result matters because antimicrobial peptides can kill bacteria rapidly but often lack the selectivity and drug-like behavior needed for clinical use. An inactive or attenuated prodrug that becomes active around a target organism could, in principle, limit exposure elsewhere. The new findings establish that design concept in bacterial cultures; they do not establish a treatment for infection.

How the molecular switch works

The researchers started with D-Bac8C Leu2,5, a positively charged antimicrobial peptide. They attached negatively charged amino-acid sequences intended to mask the peptide’s charge and prevent its usual molecular interactions until the added segment was removed.

The proposed trigger was PaAP, an extracellular aminopeptidase secreted by *P. aeruginosa*. Two masked variants were compared. The version carrying an EEEE sequence was processed slowly and incompletely and retained little antimicrobial activity. A second version, carrying an ELEG sequence, was processed more efficiently and restored bactericidal activity.

The experiments combined enzymatic digestion and analysis of processing intermediates with bacterial growth curves, biofilm metabolic measurements and staining of damaged cells. The principal bacterial model was the PA14 strain of *P. aeruginosa*, including a strain lacking PaAP. The team also compared activity across other members of the clinically important ESKAPEE pathogen group and performed laboratory selection experiments to examine emerging resistance.

What the experiments found

The ELEG-masked peptide suppressed planktonic *P. aeruginosa* and reduced activity in established biofilms after activation. PaAP was particularly important for complete processing in biofilms, where partially cleaved intermediates accumulated and killing followed a two-phase pattern.

Activity was reduced against the other tested pathogens, supporting relative species selectivity under the experimental conditions. That distinction is important: the work does not show that activation is exclusive to *P. aeruginosa* in the human body. The PaAP-deficient strain could still be inhibited under some conditions, indicating that additional bacterial enzymes or incomplete processing pathways may contribute.

When the researchers selected bacteria with reduced susceptibility, they found mutations involving lipopolysaccharide biosynthesis. The mutation patterns differed between bacteria exposed to the unmasked peptide and those exposed to the prodrug, with limited cross-resistance. This does not make the prodrug resistance-proof; it identifies possible evolutionary routes that later development would need to monitor.

Why the evidence remains preliminary

These were biochemical and microbiological experiments, not an animal infection study or clinical trial. Laboratory biofilms cannot reproduce drug distribution, immune responses, tissue toxicity, clearance or the chemical environment of a human infection. PaAP expression may also vary among clinical isolates and across stages or locations of infection.

The study therefore cannot determine an effective dose, therapeutic window or whether the mask meaningfully reduces harm to human cells. It also does not establish how the prodrug would behave in blood, lung secretions, wounds or mixed microbial communities containing other proteases.

Carbapenem-resistant *P. aeruginosa* remains on the World Health Organization’s high-priority pathogen list, so new antimicrobial strategies have a clear research rationale. The practical next steps are testing diverse clinical isolates, host-cell toxicity and serum stability, followed by pharmacokinetic and efficacy studies in relevant infection models. Until those questions are answered, this peptide is best understood as a targeted drug-design platform rather than a prospective clinical therapy.